Illinois is currently home to 2616 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The COCOA-PAD II Trial
NCT04794530
Recruiting
Among people with peripheral artery disease (PAD) age 55 and older, the investigators will test the hypothesis that PAD participants randomized to cocoa flavanols will have greater improvement or less decline in six-minute walk distance at six-month follow-up, compared to those randomized to placebo. The study will randomize 190 participants with PAD age 55 and older to one of two groups for six months: cocoa flavanols vs placebo. Our primary outcome is change in six-minute walk distance at six-... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/30/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Peripheral Artery Disease
Register for Updates
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02366819
Recruiting
This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Hektoen Inst for Medical Resrch on behalf of itself and John H Stroger Hosp, Chicago, Illinois
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Reward and Drug Effects on Mood and Brain Response
NCT04512365
Recruiting
The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
04/29/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Cannabis Use, Healthy
Register for Updates
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05521191
Recruiting
Primary Objectives * To assess the safety and tolerability of RGLS8429 * To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives * To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) * To characterize the pharmacokinetic (PK) properties of RGLS8429 * To assess the impact of RGLS8429 on renal function
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/27/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Register for Updates
Furthering Equity Through Infant Feeding EDucation and Support
NCT05441709
Recruiting
The purpose of this study is to identify whether adding clinically integrated breastfeeding peer counseling (ci-BPC) to standard lactation care is associated with a reduction in disparities in breastfeeding intensity and duration for Black and Hispanic/Latine families.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/26/2024
Locations: Swedish Hospital, Chicago, Illinois
Conditions: Breastfeeding
Register for Updates
Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma
NCT06327477
Recruiting
This phase I/II trial studies the side effects and best dose of proton-spatially fractionated radiotherapy (P-SFRT) and to see how well it works with standard radiation therapy in treating patients with newly diagnosed retroperitoneal soft tissue sarcoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard spatially fractionated radiotherapy (SFRT) refers to how the radiation is delivered to the tumor. SFRT means that differ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Retroperitoneal Sarcoma
Register for Updates
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT04471974
Recruiting
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular growth in certain types of tumors, including castrate resistant prostate cancer. Enzalutamide has been shown to block testosterone from reaching prostate cancer cells by binding to a receptor on prostate cancer cells, calle... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: University of Chicago, Evergreen Park, Illinois
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
NCT06073431
Recruiting
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Carle Cancer Center NCORP (CARLE), Urbana, Illinois
Conditions: Cancer Cachexia (CC)
Register for Updates
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
NCT05696613
Recruiting
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Insight Hospital and Medical Center Chicago, Chicago, Illinois
Conditions: Primary Membranous Nephropathy
Register for Updates
Personalized GI Motility Responses to Diet
NCT06386471
Recruiting
The goal of this randomized, crossover, clinical trial is to link: 1) gastrointestinal motility patterns induced by acute consumption of whole and refined grains, 2) enteric microbial production of bioactive metabolites, and 3) circulating postprandial appearance of metabolites important to cardiometabolic health including glucose, triglycerides, and cholesterol. Participants will be asked to consume a Smartpill monitoring device that records metrics of gastrointestinal motility in response to... Read More
Gender:
ALL
Ages:
Between 21 years and 63 years
Trial Updated:
04/23/2024
Locations: University of Illinois at Urbana-Champaign, Urbana, Illinois
Conditions: Nutritional and Metabolic Diseases, Gastrointestinal Dysfunction, Cardiovascular Diseases, Dysbiosis
Register for Updates
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Recruiting
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/23/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Register for Updates